Cargando…

A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014

BACKGROUND: Norovirus (NoV) is the major cause of acute gastroenteritis across all age groups. In particular, variants of genogroup II, genotype 4 (GII.4) have been associated with epidemics globally, occurring approximately every three years. The pandemic GII.4 variant, Sydney 2012, was first repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Kun Lee, Hewitt, Joanne, Sitabkhan, Alefiya, Eden, John-Sebastian, Lun, Jennifer, Levy, Avram, Merif, Juan, Smith, David, Rawlinson, William D., White, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846056/
https://www.ncbi.nlm.nih.gov/pubmed/27116221
http://dx.doi.org/10.1371/journal.pone.0145254
_version_ 1782429028757536768
author Lim, Kun Lee
Hewitt, Joanne
Sitabkhan, Alefiya
Eden, John-Sebastian
Lun, Jennifer
Levy, Avram
Merif, Juan
Smith, David
Rawlinson, William D.
White, Peter A.
author_facet Lim, Kun Lee
Hewitt, Joanne
Sitabkhan, Alefiya
Eden, John-Sebastian
Lun, Jennifer
Levy, Avram
Merif, Juan
Smith, David
Rawlinson, William D.
White, Peter A.
author_sort Lim, Kun Lee
collection PubMed
description BACKGROUND: Norovirus (NoV) is the major cause of acute gastroenteritis across all age groups. In particular, variants of genogroup II, genotype 4 (GII.4) have been associated with epidemics globally, occurring approximately every three years. The pandemic GII.4 variant, Sydney 2012, was first reported in early 2012 and soon became the predominant circulating NoV strain globally. Despite its broad impact, both clinically and economically, our understanding of the fundamental diversity and mechanisms by which new NoV strains emerge remains limited. In this study, we describe the molecular epidemiological trends of NoV-associated acute gastroenteritis in Australia and New Zealand between January 2013 and June 2014. METHODOLOGY: Overall, 647 NoV-positive clinical faecal samples from 409 outbreaks and 238 unlinked cases of acute gastroenteritis were examined by RT-PCR and sequencing. Phylogenetic analysis was then performed to identify NoV capsid genotypes and to establish the temporal dominance of circulating pandemic GII.4 variants. Recombinant viruses were also identified based on analysis of the ORF1/2 overlapping region. FINDINGS: Peaks in NoV activity were observed, however the timing of these epidemics varied between different regions. Overall, GII.4 NoVs were the dominant cause of both outbreaks and cases of NoV-associated acute gastroenteritis (63.1%, n = 408/647), with Sydney 2012 being the most common GII.4 variant identified (98.8%, n = 403/408). Of the 409 reported NoV outbreaks, aged-care facilities were the most common setting in both Western Australia (87%, n = 20/23) and New Zealand (58.1%, n = 200/344) while most of the NoV outbreaks were reported from hospitals (38%, n = 16/42) in New South Wales, Australia. An analysis of a subset of non-GII.4 viruses from all locations (125/239) showed the majority (56.8%, n = 71/125) were inter-genotype recombinants. These recombinants were surprisingly diverse and could be classified into 18 distinct recombinant types, with GII.P16/GII.13 (24% of recombinants) the most common. CONCLUSION: This study revealed that following its emergence in 2012, GII.4 Sydney 2012 variant continued to be the predominant cause of NoV-associated acute gastroenteritis in Australia and New Zealand between 2013 and 2014.
format Online
Article
Text
id pubmed-4846056
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48460562016-05-05 A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014 Lim, Kun Lee Hewitt, Joanne Sitabkhan, Alefiya Eden, John-Sebastian Lun, Jennifer Levy, Avram Merif, Juan Smith, David Rawlinson, William D. White, Peter A. PLoS One Research Article BACKGROUND: Norovirus (NoV) is the major cause of acute gastroenteritis across all age groups. In particular, variants of genogroup II, genotype 4 (GII.4) have been associated with epidemics globally, occurring approximately every three years. The pandemic GII.4 variant, Sydney 2012, was first reported in early 2012 and soon became the predominant circulating NoV strain globally. Despite its broad impact, both clinically and economically, our understanding of the fundamental diversity and mechanisms by which new NoV strains emerge remains limited. In this study, we describe the molecular epidemiological trends of NoV-associated acute gastroenteritis in Australia and New Zealand between January 2013 and June 2014. METHODOLOGY: Overall, 647 NoV-positive clinical faecal samples from 409 outbreaks and 238 unlinked cases of acute gastroenteritis were examined by RT-PCR and sequencing. Phylogenetic analysis was then performed to identify NoV capsid genotypes and to establish the temporal dominance of circulating pandemic GII.4 variants. Recombinant viruses were also identified based on analysis of the ORF1/2 overlapping region. FINDINGS: Peaks in NoV activity were observed, however the timing of these epidemics varied between different regions. Overall, GII.4 NoVs were the dominant cause of both outbreaks and cases of NoV-associated acute gastroenteritis (63.1%, n = 408/647), with Sydney 2012 being the most common GII.4 variant identified (98.8%, n = 403/408). Of the 409 reported NoV outbreaks, aged-care facilities were the most common setting in both Western Australia (87%, n = 20/23) and New Zealand (58.1%, n = 200/344) while most of the NoV outbreaks were reported from hospitals (38%, n = 16/42) in New South Wales, Australia. An analysis of a subset of non-GII.4 viruses from all locations (125/239) showed the majority (56.8%, n = 71/125) were inter-genotype recombinants. These recombinants were surprisingly diverse and could be classified into 18 distinct recombinant types, with GII.P16/GII.13 (24% of recombinants) the most common. CONCLUSION: This study revealed that following its emergence in 2012, GII.4 Sydney 2012 variant continued to be the predominant cause of NoV-associated acute gastroenteritis in Australia and New Zealand between 2013 and 2014. Public Library of Science 2016-04-26 /pmc/articles/PMC4846056/ /pubmed/27116221 http://dx.doi.org/10.1371/journal.pone.0145254 Text en © 2016 Lim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lim, Kun Lee
Hewitt, Joanne
Sitabkhan, Alefiya
Eden, John-Sebastian
Lun, Jennifer
Levy, Avram
Merif, Juan
Smith, David
Rawlinson, William D.
White, Peter A.
A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title_full A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title_fullStr A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title_full_unstemmed A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title_short A Multi-Site Study of Norovirus Molecular Epidemiology in Australia and New Zealand, 2013-2014
title_sort multi-site study of norovirus molecular epidemiology in australia and new zealand, 2013-2014
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846056/
https://www.ncbi.nlm.nih.gov/pubmed/27116221
http://dx.doi.org/10.1371/journal.pone.0145254
work_keys_str_mv AT limkunlee amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT hewittjoanne amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT sitabkhanalefiya amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT edenjohnsebastian amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT lunjennifer amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT levyavram amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT merifjuan amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT smithdavid amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT rawlinsonwilliamd amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT whitepetera amultisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT limkunlee multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT hewittjoanne multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT sitabkhanalefiya multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT edenjohnsebastian multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT lunjennifer multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT levyavram multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT merifjuan multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT smithdavid multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT rawlinsonwilliamd multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014
AT whitepetera multisitestudyofnorovirusmolecularepidemiologyinaustraliaandnewzealand20132014